Il2 muteins and uses thereof
AssigneesElpiscience (Suzhou) Biopharma, Ltd., Elpiscience Biopharma, Ltd.
InventorsXiang XU, Jinfeng ZHAO, Zhihao WU, Hongtao LU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to IL2 muteins (or “IL2 mutants”), an isolated polynucleotide encoding the IL2 mutein, an isolated vector containing the polynucleotide, a host cell containing the isolated polynucleotide or the isolated vector which encoding the IL2 mutein, a fusion protein containing the IL2 mutein, a pharmaceutical composition containing the IL2 mutein/muteins, and uses of such molecules in IL2 immunotherapy.
Claims28
An IL2 mutein, wherein the IL2 mutein with reduced or abolished binding to IL2Rα comprises an amino acid sequence comprising the amino acid substitution C125V or C125S as compared to wild type IL2 of SEQ ID NO:1.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.